PrimeLink to Present Preclinical Data of Two ADC Programs at AACR 2025

PrimeLink announces that the preclinical data for two innovative ADC programs (PLB-001, a novel anti-DLL3 ADC; PLB-002, a next generation anti-Claudin 6 nanobody ADC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held from April 25 to April 30, 2025, in Chicago, Illinois.

Information for the posters are as follow:

▌Title: PLB-001, a novel anti-DLL3 ADC with topoisomerase I inhibitor-based linker-payload for treatment of SCLC

Abstract Number: 4746

Location：Poster Section 35

Session Date and Time：4/29/2025, 9:00 AM ~ 12:00 PM

▌Title: PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer

Abstract Number：2945

Location：Poster Section 17

Session Date and Time：4/28/2025, 2:00 PM ~ 5:00 PM

About PrimeLink BioTherapeutics
PrimeLink BioTherapeutics is a next-generation antibody-drug conjugate (ADC) company redefining targeted cancer therapy through innovative platform technologies. Our proprietary hydrophilic linker is highly compatible with a broad range of payloads, conjugation chemistries, and antibody formats—enabling the development of structurally diverse ADCs with distinct mechanisms of action. This versatility increases the likelihood of identifying the optimal ADC candidate for each tumor target.

Our ADCs demonstrate enhanced stability in circulation and extended pharmacokinetics compared to naked antibodies, resulting in a more favorable therapeutic window. The platform also supports the rational design of dual-payload ADCs with tunable drug-to-antibody ratios (DARs), ranging from 1:1 to 1:5, and high DARs up to 24, while maintaining excellent solubility, stability, and developability.

Our lead ADC program is currently in IND-enabling studies, backed by a robust pipeline of novel modalities and mechanisms aimed at overcoming resistance and achieving deep, durable responses in hard-to-treat solid tumors.

About PLB-001

PLB-001 is a preclinical antibody-drug conjugate (ADC) targeting DLL3 (delta-like ligand 3) and incorporating a topoisomerase I inhibitor payload, conjugated via PrimeLink’s proprietary hydrophilic linker technology. It was selected as the lead candidate from PrimeLink’s integrated cascade screening platform which systematically evaluates diverse antibody–linker–payload combinations to optimize therapeutic index and translational potential. In preclinical studies, PLB-001 demonstrated potent antitumor activity across a panel of SCLC cell lines with heterogeneous DLL3 expression, as well as sustained tumor regression in multiple xenograft models. The candidate also exhibited a favorable pharmacokinetic profile, supporting its advancement toward IND-enabling studies.

About PLB-002

PLB-02 is a next-generation antibody-drug conjugate (ADC) targeting Claudin 6, developed using PrimeLink’s proprietary hydrophilic linker platform. The construct features a differentiated molecular design, with VHH-Fc conjugated to eribulin, an approved tubulin inhibitor. PrimeLink’s linker system balanced the ADC stability and hydrophilicity, mitigating the inherent hydrophobicity of the VHH-Fc format and extending the pharmacokinetics of the ADC. In preclinical studies, PLB-02 has demonstrated potent antitumor activity across multiple tumor models. Importantly, in non-human primate studies, PLB-02 exhibited a favorable safety profile, with no dose-limiting toxicities observed, supporting a wide therapeutic index. The candidate is currently advancing through IND-enabling studies.